Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Smoke Exposure, Influenza
Interventions: LAIV nasal vaccine is chosen as a model viral infection, Wood smoke, Placebo for LAIV nasal vaccine is chosen as a model viral infection, Placebo for Wood Smoke (clean Air Exposure); Biological · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 49 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 13 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Post Traumatic Stress Disorder (PTSD)
Interventions: Stellate Ganglion Block injection with ropivicane, Placebo Procedure; Procedure
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Interventions: Glargine, IV insulin, Electrolyte Correction, Correction of Fluid Loss; Drug · Other
Lead sponsor: Chattanooga-Hamilton County Hospital Authority; Other
Eligibility: 1 Year to 21 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Intrauterine Adhesions
Interventions: Seprafilm, Sterile Saline Solution; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: New York, New York

Conditions: Alcohol Withdrawal
Interventions: Ketamine, Dexmedetomidine, Normal saline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Metastatic Non Small Cell Lung Cancer
Interventions: Pembrolizumab/Vibostolimab coformulation, Docetaxel, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more

Conditions: Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity, Alcohol Withdrawal Hallucinosis, Alcohol Withdrawal-Induced Delirium Tremens
Interventions: Dexmedetomidine, Placebos; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 89 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 7
States / cities: Colorado Springs, Colorado • Denver, Colorado • Lakewood, Colorado + 2 more

Conditions: Acute Ischemic Stroke
Interventions: Intravenous tenecteplase (TNK), Placebo; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Clostridia Difficile Colitis, Clostridium; Sepsis
Interventions: Bezlotoxumab, Normal Saline; Biological · Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Wound Heal
Interventions: Free Gingival Graft Procedure; Procedure
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Sepsis, Septic Shock, Metabolic Disturbance
Interventions: vitamin C, vitamin B1, hydrocortisone, Normal saline; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Phoenix, Arizona • Boston, Massachusetts • Cambridge, Massachusetts + 6 more

Conditions: Out-Of-Hospital Cardiac Arrest
Interventions: Placebo, sodium nitrite 45 mg, sodium nitrite 60 mg; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions: Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more

Conditions: Pre-Eclampsia, Hypertension in Pregnancy, Pregnancy Complications, Hypertension, Pregnancy-Induced
Interventions: Furosemide, Placebo; Drug · Other
Lead sponsor: Melanie Maykin, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Ischemic Stroke
Interventions: Verapamil and Magnesium Sulfate, Placebo; Drug · Other
Lead sponsor: Justin Fraser; Other
Eligibility: 18 Years to 101 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Type 1 Diabetes Mellitus
Interventions: mAb hOKT3gamma1(Ala-Ala), Teplizumab, Placebo Arm; Drug
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 30 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 4
States / cities: San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 1 more

Conditions: Glomerulonephritis, Membranous
Interventions: Belimumab 10 mg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: St Louis, Missouri • Chapel Hill, North Carolina

Conditions: Shingles, Herpes Zoster
Interventions: Zostavax, HZ/su vaccine, Placebo; Biological
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions: Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 38
States / cities: Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more

Conditions: Hallux Valgus
Interventions: TLC590, Naropin®, Normal Saline, Bupivacaine; Drug
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more

Conditions: Complex Regional Pain Syndromes
Interventions: Ketamine, Midazolam, Normal Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2099
U.S. locations: 1
States / cities: Stanford, California

Conditions: Knee Osteoarthritis, Acute Pain, Anesthesia, Local, Regional Anesthesia
Interventions: ropivacaine 0.25% with epinephrine and 6mg dexamethasone, Saline; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: AL Amyloidosis
Interventions: CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 26
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 20 more

Search by objective public record fields.

Woodsmoke Exposure, Influenza Infection, and Nasal Immunity

Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa

A Randomized, Placebo-Controlled Trial of Stellate Ganglion Block in the Treatment of Post Traumatic Stress Disorder

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy

Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)

Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant

Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

Effects of StellaLife Oral Care Recovery Kit on Palatal Wound Healing After Free Gingival Graft

Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial

Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

Furosemide vs. Placebo for Severe Antepartum Hypertension

Magnesium And Verapamil After Recanalization in Ischemia of the Cerebrum: a Clinical and Translational Study.

Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes

Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

Ketamine and Midazolam Infusions for CRPS: Feasibility Study

iPACK Block With Dexamethasone For Total Knee Replacement

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)